Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,605 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study.
Jang JH, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N, Fujisaki T, Kosugi H, Matsumura I, Sasaki K, Kizaki M, Sawa M, Hidaka M, Kobayashi N, Ichikawa S, Yonemura Y, Enokitani K, Matsuda A, Ozawa K, Mitani K, Lee JW, Nakao S. Jang JH, et al. Among authors: miyazaki k. Br J Haematol. 2021 Jan;192(1):190-199. doi: 10.1111/bjh.17190. Epub 2020 Nov 5. Br J Haematol. 2021. PMID: 33152120 Free PMC article. Clinical Trial.
Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.
Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, Kirito K, Yonemura Y, Mori S, Usuki K, Iwato K, Hashino S, Wei H, Lizambri R. Shirasugi Y, et al. Among authors: miyazaki k. Int J Hematol. 2011 Jul;94(1):71-80. doi: 10.1007/s12185-011-0886-8. Epub 2011 Jun 25. Int J Hematol. 2011. PMID: 21706145 Clinical Trial.
An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).
Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Iwato K, Okamoto S, Kurokawa M, Kirito K, Hashino S, Ninomiya H, Mori S, Yonemura Y, Usuki K, Wei H, Lizambri R. Shirasugi Y, et al. Among authors: miyazaki k. Int J Hematol. 2012 Jun;95(6):652-9. doi: 10.1007/s12185-012-1065-2. Epub 2012 Apr 25. Int J Hematol. 2012. PMID: 22532046 Clinical Trial.
Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study.
Nakagawa Y, Suzuki K, Hirose T, Chou T, Fujisawa S, Kida M, Usuki K, Ishida Y, Taniguchi S, Kouzai Y, Tomoyasu S, Miyazaki K, Higashihara M, Ando K, Aoki S, Arai A, Akiyama N, Hatake K, Okamoto S, Dan K, Ohyashiki K, Urabe A. Nakagawa Y, et al. Among authors: miyazaki k. J Infect Chemother. 2011 Feb;17(1):58-67. doi: 10.1007/s10156-010-0075-3. Epub 2010 Jul 3. J Infect Chemother. 2011. PMID: 20602137 Clinical Trial.
Relationship between response to lusutrombopag and splenic volume.
Uojima H, Arase Y, Itokawa N, Atsukawa M, Satoh T, Miyazaki K, Hidaka H, Sung JH, Kako M, Tsuruya K, Kagawa T, Iwakiri K, Horie R, Koizumi W. Uojima H, et al. Among authors: miyazaki k. World J Gastroenterol. 2018 Dec 14;24(46):5271-5279. doi: 10.3748/wjg.v24.i46.5271. World J Gastroenterol. 2018. PMID: 30581275 Free PMC article.
Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma.
Nakazato T, Hagihara M, Sahara N, Tamai Y, Ishii R, Tamaki S, Wake A, Tajika K, Sakai R, Kobayashi T, Hua J, Inoue M, Aisa Y, Fujisawa S, Miyazaki K, Irie S, Tanaka E, Higashihara M. Nakazato T, et al. Among authors: miyazaki k. Ann Hematol. 2021 Nov;100(11):2745-2754. doi: 10.1007/s00277-021-04592-y. Epub 2021 Jul 31. Ann Hematol. 2021. PMID: 34333665 Clinical Trial.
2,605 results